Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma

Krish Patel; Alexey V. Danilov; John M. Pagel

doi:10.1182/blood.2019001795

Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma

Krish Patel, Alexey V. Danilov, John M. Pagel

Knight Cancer Institute

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL) represent indolent malignancies characterized by multiple episodes of relapse. Therapy has centered on agents that largely target the B-cell receptor pathway. Duvelisib is a second-generation oral inhibitor of phosphoinositide-3 kinase, downstream of the B-cell receptor pathway, approved in the United States for relapsed CLL/SLL and FL. Duvelisib represents a highly active agent, and ongoing investigations, including fixed-duration drug combinations and alternative dosing schedules, are aimed at reducing immune-mediated toxicities.

Original language	English (US)
Pages (from-to)	1573-1577
Number of pages	5
Journal	Blood
Volume	134
Issue number	19
DOIs	https://doi.org/10.1182/blood.2019001795
State	Published - 2019

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood.2019001795

Cite this

@article{ec805cd026574b0db396a5eed35e1e5e,

title = "Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma",

abstract = "Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL) represent indolent malignancies characterized by multiple episodes of relapse. Therapy has centered on agents that largely target the B-cell receptor pathway. Duvelisib is a second-generation oral inhibitor of phosphoinositide-3 kinase, downstream of the B-cell receptor pathway, approved in the United States for relapsed CLL/SLL and FL. Duvelisib represents a highly active agent, and ongoing investigations, including fixed-duration drug combinations and alternative dosing schedules, are aimed at reducing immune-mediated toxicities.",

author = "Krish Patel and Danilov, {Alexey V.} and Pagel, {John M.}",

note = "Publisher Copyright: {\textcopyright} 2019 by The American Society of Hematology",

year = "2019",

doi = "10.1182/blood.2019001795",

language = "English (US)",

volume = "134",

pages = "1573--1577",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "19",

}

TY - JOUR

T1 - Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma

AU - Patel, Krish

AU - Danilov, Alexey V.

AU - Pagel, John M.

PY - 2019

Y1 - 2019

N2 - Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL) represent indolent malignancies characterized by multiple episodes of relapse. Therapy has centered on agents that largely target the B-cell receptor pathway. Duvelisib is a second-generation oral inhibitor of phosphoinositide-3 kinase, downstream of the B-cell receptor pathway, approved in the United States for relapsed CLL/SLL and FL. Duvelisib represents a highly active agent, and ongoing investigations, including fixed-duration drug combinations and alternative dosing schedules, are aimed at reducing immune-mediated toxicities.

AB - Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL) represent indolent malignancies characterized by multiple episodes of relapse. Therapy has centered on agents that largely target the B-cell receptor pathway. Duvelisib is a second-generation oral inhibitor of phosphoinositide-3 kinase, downstream of the B-cell receptor pathway, approved in the United States for relapsed CLL/SLL and FL. Duvelisib represents a highly active agent, and ongoing investigations, including fixed-duration drug combinations and alternative dosing schedules, are aimed at reducing immune-mediated toxicities.

UR - http://www.scopus.com/inward/record.url?scp=85074674829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074674829&partnerID=8YFLogxK

U2 - 10.1182/blood.2019001795

DO - 10.1182/blood.2019001795

M3 - Article

C2 - 31554637

AN - SCOPUS:85074674829

SN - 0006-4971

VL - 134

SP - 1573

EP - 1577

JO - Blood

JF - Blood

IS - 19

ER -

Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this